HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMPACT THERAP-B

14.070

+0.1401.01%

Volume:9.63M

Turnover:138.60M

Market Cap:3.97B

PE:-10.87

High:15.110

Open:14.100

Low:13.700

Close:13.930

52wk High:47.980

52wk Low:10.310

Shares:282.46M

HK Float Shares:282.46M

Volume Ratio:1.42

T/O Rate:3.41%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.295

ROE:--

ROA:-40.35%

PB:4.39

PE(LYR):-10.87

PS:28.78

Loading ...

Overview Company News Filings

Impact Therapeutics CEO Cai Lifts Stake to 6.56% After Buying 100,000 Shares at Hk$14.61 Each

IMPACT Therapeutics CEO Increases Personal Stake to 6.56% via HK$1.46 Million On-Market Purchase

Bulletin Express

Impact Therapeutics - CEO Purchases 100,000 Ordinary Shares at Hk$14.6105 Per Share

THOMSON REUTERS

Impact Therapeutics Says Senaparib EU Marketing Application Under EMA Review, Approval Eyed in 2H 2026

Impact Therapeutics FY26 H1 Net Loss Narrows 29.5% to RMB 90.81 Million; Revenue Rises to RMB 105.19 Million

IMPACT Therapeutics to Join Hang Seng Composite Index

MT Newswires Live

IMPACT Therapeutics to Enter Hang Seng Composite Index, Unlocks Stock Connect Access from 7 September 2026

Bulletin Express

IMPACT THERAP-B (07630) Set to Join Hang Seng Composite Index, Paving Way for Stock Connect Inclusion

IMPACT Therapeutics Sets 31 Aug 2026 Board Meeting to Approve H1 2026 Unaudited Results

Bulletin Express

Impact Therapeutics Schedules Board Meeting to Review Interim Results

Hong Kong Stock Market Moves: IMPACT THERAP-B Rises Over 3% on Expected Interim Loss Reduction and IMP2794 PCC Nomination

IMPACT THERAP-B Designates IMP2794 as Preclinical Candidate, a Highly Selective KAT6A PROTAC from Its Proprietary Platform

Impact Therapeutics Names Imp2794 KAT6A Protac Degrader as Preclinical Candidate

Impact Therapeutics - Announces Imp2794 as Kat6a-Specific Preclinical Candidate

THOMSON REUTERS

IMPACT Therapeutics forecasts 276%–359% revenue surge and narrower interim loss

Bulletin Express

Impact Therapeutics - Expects Revenue of Rmb94.7 Mln-Rmb115.7 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS

Impact Therapeutics Expects H1 Loss to Narrow to RMB 81.7 Million-RMB 99.9 Million

IMPACT Therapeutics Maintains 282.46 Million Issued H Shares and Confirms Public Float Compliance for July 2026

Bulletin Express

Hong Kong Stock Moves | <b>IMPACT THERAP-B</b> (07630) Plunges Over 13% in Afternoon Trade, Down Nearly 70% Since Early July, Total Market Cap Falls Below HK$3.5 Billion

Impact Therapeutics Licenses Senaparib Rights to Pharmanovia in Europe, Mideast, North Africa, Australia, New Zealand for up to EUR 423.5 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/07630/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"07630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"IMPACT THERAP-B","latestPrice":14.07,"timestamp":1790755706167,"preClose":13.93,"halted":0,"volume":9625600,"delay":0,"changeRate":0.010050251256281449,"floatShares":282461530,"shares":282461530,"eps":-1.294715,"marketStatus":"Closed National Day","change":0.14,"latestTime":"09-30 16:08:26","open":14.1,"high":15.11,"low":13.7,"amount":138596679,"amplitude":0.10122,"askPrice":14.07,"askSize":8000,"bidPrice":14,"bidSize":24800,"shortable":0,"etf":0,"ttmEps":-1.052,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":7,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":13.93,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":1.4239474540835402,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","floatShares":282461530,"roa":"-40.35%","roe":"--","lyrEps":-1.294715,"volumeRatio":1.4239474540835402,"shares":282461530,"dividePrice":0,"high":15.11,"amplitude":0.10122,"preClose":13.93,"low":13.7,"week52Low":10.31,"pbRate":"4.39","psRate":"28.78","week52High":47.98,"institutionHeld":0,"latestPrice":14.07,"committee":0.512195,"eps":-1.294715,"divideRate":0,"volume":9625600,"delay":0,"ttmEps":-1.052,"open":14.1,"prevYearClose":20.1,"prevWeekClose":13.5,"prevMonthClose":14.07,"prevQuarterClose":14.07,"fiveDayClose":15.15,"twentyDayClose":13.38,"sixtyDayClose":19.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/07630\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"07630","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"07630\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"07630\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1782230400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/07630\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"07630","date":"2026-09-30","current":-13.374525,"percent":0.525773,"low":-34.323153,"twenty":-29.923784,"median":-13.405621,"eighty":-10.552154,"high":-8.821219,"avg":-18.259383,"sd":8.978018,"marketCap":3974233727},"quantilePoints":[{"date":"2026-05-15","current":-32.36994,"twenty":-32.973318,"median":-32.357426,"eighty":-26.127101,"marketCap":11057651805},{"date":"2026-05-22","current":-30.548005,"twenty":-32.354923,"median":-30.958502,"eighty":-28.393426,"marketCap":10411425401},{"date":"2026-05-29","current":-32.218614,"twenty":-32.294393,"median":-30.958502,"eighty":-30.148817,"marketCap":11018988687},{"date":"2026-06-05","current":-29.849738,"twenty":-32.359929,"median":-31.257987,"eighty":-30.148817,"marketCap":10223633112},{"date":"2026-06-12","current":-29.369689,"twenty":-32.33377,"median":-30.548005,"eighty":-29.705347,"marketCap":10052410732},{"date":"2026-06-18","current":-29.78235,"twenty":-32.303072,"median":-30.338658,"eighty":-29.742668,"marketCap":10218109810},{"date":"2026-06-26","current":-29.297581,"twenty":-32.241427,"median":-30.11999,"eighty":-29.607619,"marketCap":10002701008},{"date":"2026-07-03","current":-16.26247,"twenty":-32.218614,"median":-29.994357,"eighty":-29.297581,"marketCap":5556442415},{"date":"2026-07-10","current":-15.780707,"twenty":-31.493905,"median":-29.916258,"eighty":-25.475578,"marketCap":5385220035},{"date":"2026-07-17","current":-11.297625,"twenty":-31.022068,"median":-29.816044,"eighty":-15.922995,"marketCap":3869073471},{"date":"2026-07-24","current":-9.271485,"twenty":-30.958502,"median":-29.609087,"eighty":-15.602668,"marketCap":3175898995},{"date":"2026-07-31","current":-10.646015,"twenty":-30.630104,"median":-29.369689,"eighty":-13.307417,"marketCap":3653664669},{"date":"2026-08-07","current":-10.047131,"twenty":-30.493855,"median":-29.24895,"eighty":-10.58915,"marketCap":3454825776},{"date":"2026-08-14","current":-10.299125,"twenty":-30.36699,"median":-25.475578,"eighty":-10.316459,"marketCap":3545960269},{"date":"2026-08-21","current":-10.772628,"twenty":-30.33128,"median":-16.418396,"eighty":-10.292557,"marketCap":3717182649},{"date":"2026-08-28","current":-12.490535,"twenty":-30.224959,"median":-15.896725,"eighty":-10.316459,"marketCap":4310937679},{"date":"2026-09-04","current":-14.62831,"twenty":-30.072679,"median":-15.691688,"eighty":-10.353511,"marketCap":4403575252},{"date":"2026-09-11","current":-12.087934,"twenty":-30.026033,"median":-14.57977,"eighty":-10.495083,"marketCap":3643753737},{"date":"2026-09-18","current":-12.193817,"twenty":-29.977617,"median":-13.665771,"eighty":-10.535977,"marketCap":3680473735},{"date":"2026-09-25","current":-12.65778,"twenty":-29.936332,"median":-13.862539,"eighty":-10.54718,"marketCap":3813230655},{"date":"2026-09-30","current":-13.167654,"twenty":-29.923784,"median":-13.405621,"eighty":-10.552154,"marketCap":3974233727}],"updateTime":1790841443692},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"07630\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664131847","title":"Impact Therapeutics CEO Cai Lifts Stake to 6.56% After Buying 100,000 Shares at Hk$14.61 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2664131847","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664131847?lang=en_us&edition=fundamental","pubTime":"2026-09-03 08:33","pubTimestamp":1788395580,"startTime":"0","endTime":"0","summary":"Impact Therapeutics CEO Cai lifts stake to 6.56% after buying 100,000 shares at HK$14.61 eachCEO Sui Xiong Cai bought 100,000 ordinary shares in the open market, lifting his stake to 6.56%.Purchase pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL1nSkS9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Impact Therapeutics CEO Cai Lifts Stake to 6.56% After Buying 100,000 Shares at Hk$14.61 Each","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120376512","title":"IMPACT Therapeutics CEO Increases Personal Stake to 6.56% via HK$1.46 Million On-Market Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1120376512","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120376512?lang=en_us&edition=fundamental","pubTime":"2026-09-03 08:23","pubTimestamp":1788394986,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT THERAP-B) disclosed that Executive Director and Chief Executive Officer Dr. Sui Xiong Cai acquired 100,000 ordinary shares in the open market at an average price of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664842249","title":"Impact Therapeutics - CEO Purchases 100,000 Ordinary Shares at Hk$14.6105 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2664842249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664842249?lang=en_us&edition=fundamental","pubTime":"2026-09-03 08:02","pubTimestamp":1788393730,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44U19D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663730330","title":"Impact Therapeutics Says Senaparib EU Marketing Application Under EMA Review, Approval Eyed in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2663730330","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663730330?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:33","pubTimestamp":1788165237,"startTime":"0","endTime":"0","summary":"Impact Therapeutics says senaparib EU marketing application under EMA review, approval eyed in 2H 2026Impact Therapeutics’ senaparib ovarian-cancer maintenance filing with the EMA was accepted in Augu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL4HjK0z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663073702","title":"Impact Therapeutics FY26 H1 Net Loss Narrows 29.5% to RMB 90.81 Million; Revenue Rises to RMB 105.19 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663073702","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663073702?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:33","pubTimestamp":1788165221,"startTime":"0","endTime":"0","summary":"Impact Therapeutics FY26 H1 net loss narrows 29.5% to RMB 90.81 million; revenue rises to RMB 105.19 millionImpact Therapeutics reported revenue of RMB 105.19 million, up more than quadrupled from a y","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL7fVJfp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661268247","title":"IMPACT Therapeutics to Join Hang Seng Composite Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2661268247","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661268247?lang=en_us&edition=fundamental","pubTime":"2026-08-24 11:19","pubTimestamp":1787541578,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics (HKG:7630) will be added to the Hang Seng Composite Index from Sept. 7, according to a Monday Hong Kong bourse filing.Its shares are also expected to meet the criteria to be traded through the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HSCI","02843","YANG","CWEB","ASHS","FXP","YXI","82843","BK4539","KCAI","XPP","02822","BK1161","BK4007","BK4139","YINN","FLCH","82822","LENZ","02823","CHAU","KWEB","ASHR","KBA","07630","82823"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143127061","title":"IMPACT Therapeutics to Enter Hang Seng Composite Index, Unlocks Stock Connect Access from 7 September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1143127061","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143127061?lang=en_us&edition=fundamental","pubTime":"2026-08-24 07:50","pubTimestamp":1787529011,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. announced that Hang Seng Indexes Company Limited has selected the group as a constituent of the Hang Seng Composite Index (HSCI), effective 7 September 2026. The inclusion...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165050593","title":"IMPACT THERAP-B (07630) Set to Join Hang Seng Composite Index, Paving Way for Stock Connect Inclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=1165050593","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165050593?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:02","pubTimestamp":1787313754,"startTime":"0","endTime":"0","summary":"On August 21, 2026, Hang Seng Indexes Company unveiled the results of its quarterly index review as of June 30, 2026, with IMPACT THERAP-B (07630) being added to the Hang Seng Composite Index. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630","FLHK","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122709213","title":"IMPACT Therapeutics Sets 31 Aug 2026 Board Meeting to Approve H1 2026 Unaudited Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1122709213","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122709213?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:47","pubTimestamp":1787129230,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc announced that its board of directors will convene on 31 August 2026 to review and approve the unaudited interim financial results for the six months ended 30 June 2026. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456604","title":"Impact Therapeutics Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456604","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456604?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:38","pubTimestamp":1787128710,"startTime":"0","endTime":"0","summary":"Impact Therapeutics schedules board meeting to review interim resultsImpact Therapeutics scheduled a board meeting for Aug. 31, 2026 to review unaudited interim results for the six months ended June 3","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL59SYZv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162268658","title":"Hong Kong Stock Market Moves: IMPACT THERAP-B Rises Over 3% on Expected Interim Loss Reduction and IMP2794 PCC Nomination","url":"https://stock-news.laohu8.com/highlight/detail?id=1162268658","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162268658?lang=en_us&edition=fundamental","pubTime":"2026-08-14 13:52","pubTimestamp":1786686736,"startTime":"0","endTime":"0","summary":"Shares of IMPACT THERAP-B (07630) climbed more than 3% in early trading, last up 2.64% at HKD 12.43, with a turnover of approximately HKD 3.06 million.On the news front, IMPACT THERAP-B recently...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4212","PPC","BK4585","KCAI","VXUS","07630","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133174395","title":"IMPACT THERAP-B Designates IMP2794 as Preclinical Candidate, a Highly Selective KAT6A PROTAC from Its Proprietary Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=1133174395","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133174395?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:20","pubTimestamp":1786526417,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) announced that it has designated IMP2794 as a preclinical candidate compound (PCC), a KAT6A-specific degrader PROTAC discovered through its proprietary targeted protein...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658197808","title":"Impact Therapeutics Names Imp2794 KAT6A Protac Degrader as Preclinical Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658197808","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658197808?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:16","pubTimestamp":1786526190,"startTime":"0","endTime":"0","summary":"Impact Therapeutics names IMP2794 KAT6A PROTAC degrader as preclinical candidateImpact Therapeutics nominated IMP2794 as a preclinical candidate, its first from a proprietary targeted protein degradat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL41R3kz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978702","title":"Impact Therapeutics - Announces Imp2794 as Kat6a-Specific Preclinical Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658978702?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:16","pubTimestamp":1786526175,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128234712","title":"IMPACT Therapeutics forecasts 276%–359% revenue surge and narrower interim loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1128234712","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128234712?lang=en_us&edition=fundamental","pubTime":"2026-08-11 16:47","pubTimestamp":1786438029,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. issued a profit alert for the six months ended 30 June 2026, projecting a sharp top-line expansion and a materially reduced loss versus the prior-year period. Revenue is...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658899329","title":"Impact Therapeutics - Expects Revenue of Rmb94.7 Mln-Rmb115.7 Mln for Six Months Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658899329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658899329?lang=en_us&edition=fundamental","pubTime":"2026-08-11 16:41","pubTimestamp":1786437675,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN4480E3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658937129","title":"Impact Therapeutics Expects H1 Loss to Narrow to RMB 81.7 Million-RMB 99.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658937129","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658937129?lang=en_us&edition=fundamental","pubTime":"2026-08-11 16:41","pubTimestamp":1786437668,"startTime":"0","endTime":"0","summary":"Impact Therapeutics expects H1 loss to narrow to RMB 81.7 million-RMB 99.9 millionImpact Therapeutics guided for revenue of RMB 94.7-115.7 million for the six months ended June 30, 2026, up 276%-359%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDLbw6wN6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103430874","title":"IMPACT Therapeutics Maintains 282.46 Million Issued H Shares and Confirms Public Float Compliance for July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1103430874","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103430874?lang=en_us&edition=fundamental","pubTime":"2026-08-05 17:28","pubTimestamp":1785922107,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (H shares) filed its Monthly Return for the period ended 31 July 2026, confirming that the company’s equity structure remained unchanged during the month. • Authorised and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147623174","title":"Hong Kong Stock Moves | <b>IMPACT THERAP-B</b> (07630) Plunges Over 13% in Afternoon Trade, Down Nearly 70% Since Early July, Total Market Cap Falls Below HK$3.5 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1147623174","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147623174?lang=en_us&edition=fundamental","pubTime":"2026-08-03 14:12","pubTimestamp":1785737537,"startTime":"0","endTime":"0","summary":"According to financial information, IMPACT THERAP-B (07630) fell over 13% in the afternoon session. As of the time of writing, it was down 12.47% to HK$11.58, with a turnover of HK$5.2774 million. On...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4588","07630","KCAI","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656328122","title":"Impact Therapeutics Licenses Senaparib Rights to Pharmanovia in Europe, Mideast, North Africa, Australia, New Zealand for up to EUR 423.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656328122","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656328122?lang=en_us&edition=fundamental","pubTime":"2026-08-03 13:58","pubTimestamp":1785736690,"startTime":"0","endTime":"0","summary":"Impact Therapeutics licenses senaparib rights to Pharmanovia in Europe, Mideast, North Africa, Australia, New Zealand for up to EUR 423.5 millionImpact Therapeutics signed an exclusive license deal wi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDLpsGXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":97,"code":"91000000","status":"200"}]}}